Immuron Announces Availability of RedChip Conference Presentation
MELBOURNE, Australia, July 25, 2016 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) announces the availability of its presentation from RedChip’s Small Stocks, Big Money Investor Conference. The replay of the Company’s presentation and Q&A session can be viewed at http://www.redchip.com/events/9/small-stocks-big-money-investor-conference/imc.ax
During the presentation, Immuron’s CEO, Thomas Liquard, provides an overview of Immuron’s business and an update on multiple milestones achieved over the past six months.
RedChip’s Small Stocks, Big Money Investor Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip’s microcap conference series each year.
About Immuron
Immuron Ltd (ASX:IMC) (OTCQB:IMROY) is a microbiome company focused on developing and commercializing oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of Travelers’ diarrhea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
For more information visit: www.immuron.com
Contact: Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 thomasliquard@immuron.com Immuron US Investor Relations: Jon Cunningham RedChip Companies, Inc. US Ph: +1 (407) 644 4256, (ext. 107) jon@redchip.com
© Copyright Globe Newswire. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire.
